S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
NASDAQ:BMRN

BioMarin Pharmaceutical Stock Forecast, Price & News

$86.12
+1.88 (+2.23%)
(As of 12/7/2021 04:00 PM ET)
Add
Compare
Today's Range
$84.71
$86.62
50-Day Range
$71.72
$91.47
52-Week Range
$71.59
$92.57
Volume
1.23 million shs
Average Volume
1.20 million shs
Market Capitalization
$15.81 billion
P/E Ratio
1,076.50
Dividend Yield
N/A
Beta
0.49
30 days | 90 days | 365 days | Advanced Chart
Receive BMRN News and Ratings via Email

Sign-up to receive the latest news and ratings for BioMarin Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.


BioMarin Pharmaceutical logo

About BioMarin Pharmaceutical

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.

Headlines

BioMarin to Hold Virtual R&D Day at 11:00am ET Today
November 30, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:BMRN
CUSIP
09061G10
Employees
3,059
Year Founded
1997

Sales & Book Value

Annual Sales
$1.86 billion
Cash Flow
$1.28 per share
Book Value
$23.24 per share

Profitability

Net Income
$859.10 million
Pretax Margin
-2.65%

Debt

Price-To-Earnings

Miscellaneous

Free Float
180,490,000
Market Cap
$15.81 billion
Optionable
Optionable

Company Calendar

Last Earnings
10/26/2021
Today
12/08/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/24/2022

Social Links


MarketRank

Overall MarketRank

2.76 out of 5 stars

Medical Sector

40th out of 1,394 stocks

Pharmaceutical Preparations Industry

12th out of 673 stocks

Analyst Opinion: 4.4Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -












BioMarin Pharmaceutical (NASDAQ:BMRN) Frequently Asked Questions

Is BioMarin Pharmaceutical a buy right now?

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last twelve months. There are currently 3 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BioMarin Pharmaceutical stock.
View analyst ratings for BioMarin Pharmaceutical
or view top-rated stocks.

How has BioMarin Pharmaceutical's stock been impacted by Coronavirus?

BioMarin Pharmaceutical's stock was trading at $86.90 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, BMRN shares have decreased by 0.9% and is now trading at $86.12.
View which stocks have been most impacted by COVID-19
.

When is BioMarin Pharmaceutical's next earnings date?

BioMarin Pharmaceutical is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for BioMarin Pharmaceutical
.

How were BioMarin Pharmaceutical's earnings last quarter?

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) posted its earnings results on Tuesday, October, 26th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.05. The biotechnology company had revenue of $408.74 million for the quarter, compared to analysts' expectations of $435.29 million. BioMarin Pharmaceutical had a trailing twelve-month return on equity of 2.02% and a net margin of 0.86%. The firm's revenue for the quarter was down 14.3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.29 EPS.
View BioMarin Pharmaceutical's earnings history
.

What guidance has BioMarin Pharmaceutical issued on next quarter's earnings?

BioMarin Pharmaceutical updated its FY 2021 earnings guidance on Wednesday, November, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.82 billion-$1.88 billion, compared to the consensus revenue estimate of $1.85 billion.

What price target have analysts set for BMRN?

15 analysts have issued 1-year price objectives for BioMarin Pharmaceutical's shares. Their forecasts range from $88.00 to $152.00. On average, they anticipate BioMarin Pharmaceutical's stock price to reach $109.43 in the next year. This suggests a possible upside of 27.1% from the stock's current price.
View analysts' price targets for BioMarin Pharmaceutical
or view top-rated stocks among Wall Street analysts.

Who are BioMarin Pharmaceutical's key executives?

BioMarin Pharmaceutical's management team includes the following people:
  • Jean-Jacques Bienaimé, Chairman & Chief Executive Officer
  • Brian R. Mueller, Chief Financial Officer & Executive Vice President
  • Eduardo E. von Pervieux, Chief Information Officer
  • Henry J. Fuchs, President-Worldwide Research & Development
  • Adora Ndu, VP-World Wide Research & Development

What is Jean-Jacques Bienaimé's approval rating as BioMarin Pharmaceutical's CEO?

161 employees have rated BioMarin Pharmaceutical CEO Jean-Jacques Bienaimé on Glassdoor.com. Jean-Jacques Bienaimé has an approval rating of 94% among BioMarin Pharmaceutical's employees. This puts Jean-Jacques Bienaimé in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of BioMarin Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), (MDVN) (MDVN), Incyte (INCY), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), Vertex Pharmaceuticals (VRTX), (KITE) (KITE) and Freeport-McMoRan (FCX).

What is BioMarin Pharmaceutical's stock symbol?

BioMarin Pharmaceutical trades on the NASDAQ under the ticker symbol "BMRN."

Who are BioMarin Pharmaceutical's major shareholders?

BioMarin Pharmaceutical's stock is owned by a variety of institutional and retail investors. Top institutional investors include Primecap Management Co. CA (9.77%), Capital Research Global Investors (9.61%), Janus Henderson Group PLC (2.15%), Geode Capital Management LLC (1.27%), Manning & Napier Group LLC (0.95%) and California Public Employees Retirement System (0.76%). Company insiders that own BioMarin Pharmaceutical stock include Brian Mueller, David E I Pyott, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Michael G Grey, Richard A Meier, V Bryan Lawlis and Willard H Dere.
View institutional ownership trends for BioMarin Pharmaceutical
.

Which institutional investors are selling BioMarin Pharmaceutical stock?

BMRN stock was sold by a variety of institutional investors in the last quarter, including Alberta Investment Management Corp, Capital Research Global Investors, Neuberger Berman Group LLC, Verition Fund Management LLC, Citigroup Inc., Davide Leone & Partners Investment Co Ltd., Scout Investments Inc., and Two Sigma Advisers LP. Company insiders that have sold BioMarin Pharmaceutical company stock in the last year include Brian Mueller, George Eric Davis, Jean Jacques Bienaime, Jeffrey Robert Ajer, Michael G Grey, and Richard A Meier.
View insider buying and selling activity for BioMarin Pharmaceutical
or view top insider-selling stocks.

Which institutional investors are buying BioMarin Pharmaceutical stock?

BMRN stock was acquired by a variety of institutional investors in the last quarter, including Camber Capital Management LP, Fort Washington Investment Advisors Inc. OH, Point72 Asset Management L.P., Rockefeller Capital Management L.P., Marshall Wace LLP, Alliancebernstein L.P., Sphera Funds Management LTD., and Citadel Advisors LLC.
View insider buying and selling activity for BioMarin Pharmaceutical
or or view top insider-buying stocks.

How do I buy shares of BioMarin Pharmaceutical?

Shares of BMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioMarin Pharmaceutical's stock price today?

One share of BMRN stock can currently be purchased for approximately $86.12.

How much money does BioMarin Pharmaceutical make?

BioMarin Pharmaceutical has a market capitalization of $15.81 billion and generates $1.86 billion in revenue each year. The biotechnology company earns $859.10 million in net income (profit) each year or $0.08 on an earnings per share basis.

How many employees does BioMarin Pharmaceutical have?

BioMarin Pharmaceutical employs 3,059 workers across the globe.

When was BioMarin Pharmaceutical founded?

BioMarin Pharmaceutical was founded in 1997.

What is BioMarin Pharmaceutical's official website?

The official website for BioMarin Pharmaceutical is www.bmrn.com.

Where are BioMarin Pharmaceutical's headquarters?

BioMarin Pharmaceutical is headquartered at 770 Lindaro Street, San Rafael CA, 94901.

How can I contact BioMarin Pharmaceutical?

BioMarin Pharmaceutical's mailing address is 770 Lindaro Street, San Rafael CA, 94901. The biotechnology company can be reached via phone at (415) 506-6700, via email at [email protected], or via fax at 415-382-7889.


This page was last updated on 12/8/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.